Services

Our preferred business model is through collaboration and partnership with industry clients to develop in silico tools. At the request of the client, a service agreement could be negotiated to carry out the following services:

1. Re-analysis of archived Affymentrix GeneChip data of previous drug development programs that have been terminated due to unexplained toxicity or poor efficacy results.
2. Translation of model species data to human using cross-species tools developed at CrossGen.
3. Forward translation of model species biomarkers for clinical applications in humans by developing bridging markers.
4. Gene expression profiling of medicinal plants to characterise their toxicological effects in humans.
5. Transfer of important traits from resource rich crops to resource poor crops using cross-species technology.